## REMARKS

In the Office Action, the Examiner has required Applicants to elect a single invention among Groups (I) - (IX) to which the claims must be restricted.

Applicants hereby elect, without traverse, Group (II), claims 1-5, 7 and 8 drawn to compounds of formula (I), where Z is N, X is phenyl, cyclohexyl and Y is N-containing cyclic group; and simple compositions thereof.

In response to the species election requirement, Applicants hereby elect the compound of Example 18 (page 8: 4-isobutoxy-1H-indole-2-carboxylic acid [4-(2-azepan-1-yl)-phenyl]amide) which is a compound of formula I, wherein Z is N, X is phenyl, Q is CH2CH2 (linker 2 atoms in length), Y is azepane, R is isobutoxy, R<sup>9</sup> is H.

Applicants request rejoinder of the method claims of commensurate scope to the composition of matter claims upon allowance of claims directed to the elected invention, e.g., Applicants respectfully request rejoinder of the subject matter corresponding to Group (IX) upon allowance of the claims embodying the elected invention

Applicants respectfully request that the remarks made herein be entered and made of record in the file history of the present application. If any issues remain in connection herewith, the Examiner is respectfully invited to telephone the undersigned to discuss the same.

Respectfully submitted,

Mårk W. Milstead

Attorney for Applicant

Novartis Institutes for Biomedical Research, Inc. 220 Massachusetts Ave Cambridge, MA 02139 (617) 871-4125

Date: July 8, 2009

Reg. No. 45,825

-.2.-